儿童淋巴瘤患者腺样体、扁桃体和胸腺的18F-FDG摄取反弹性增高
回顾性分析2007至2019年212例儿童淋巴瘤患者共800次PET/CT,评估腺样体、扁桃体和胸腺FDG摄取随治疗的变化。腺样体、扁桃体和胸腺摄取阳性率在治疗结束时下降、随访期反弹,随访期SUVmax显著高于基线,腺样体和扁桃体在随访6-12个月达峰,胸腺在3-12个月内达峰。作者结论认为这些表现是常见且良性的治疗后反弹。
要点
- 儿童淋巴瘤治疗后随访中,腺样体、扁桃体和胸腺FDG摄取反弹常见且为良性表现。
- 腺样体和扁桃体摄取在随访6-12个月达峰,胸腺摄取在3-12个月内达峰。
- 随访期SUVmax显著高于基线,但年龄≥16岁患者仍可见明显摄取反弹。
核心结论
- 儿童淋巴瘤患者治疗后监测中,腺样体、扁桃体和胸腺的明显18F-FDG摄取反弹常见且为良性。
研究设计与样本
- 回顾性研究,纳入212例儿童淋巴瘤患者2007至2019年间共800次PET/CT扫描,平均年龄11.9岁,中位随访26.2个月。
关键影像表现/征象
- 腺样体、扁桃体和胸腺FDG摄取阳性分别见于513次(64%)、548次(69%)和270次(48%)扫描。
诊断标准与关键数值
- 腺样体摄取阳性率基线88%,治疗结束时降至48%,随访期反弹至73%。
- 扁桃体摄取阳性率基线79%,治疗结束时降至45%,随访期反弹至82%。
- 胸腺摄取阳性率基线75%,治疗结束时降至21%,随访期反弹至72%。
- 随访期SUVmax显著高于基线(P<0.001):腺样体7.0±3.5 vs 5.8±2.5,扁桃体9.4±3.5 vs 8.2±2.8,胸腺4.0±1.4 vs 3.4±1.1。
- 腺样体和扁桃体在随访6-12个月达峰,SUVmax分别为7.6±3.2和10.6±3.2;胸腺在3-12个月内达峰,SUVmax为4.4±1.4。
临床应用与阅片要点
- 儿童淋巴瘤治疗后随访中,腺样体、扁桃体和胸腺FDG摄取反弹常见且为良性,阅片时应结合治疗时间点识别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the treatment-dependent changes in FDG uptake in the adenoid, palatine tonsils, and thymus in paediatric patients with lymphoma.
METHODS: Eight hundred PET/CT scans of 212 paediatric patients between 2007 and 2019 (mean age, 11.9 years; median follow-up, 26.2 months) were retrospectively reviewed for discernible FDG uptake in the adenoid (A+), palatine tonsils (P+), and thymus (T+). The distribution of metabolic activity in the interested lymphoid organs was examined. Statistical analysis was performed using SPSS packages.
RESULTS: There were 513 (64 %) A + scans, 548 (69 %) P + scans, 270 (48 %) T + scans identified. The percentage of A + was 88 % at baseline, decreased to 48 % at the end of treatment, and then rebounded to 73 % during follow up; P + went from 79 % to 45 % then to 82 %; and for T + was 75 %, 21 %, 72 %. SUVmax was significantly higher (P < 0.001) in scans performed during follow-up than that of the baseline (A + 7.0 ± 3.5 vs. 5.8 ± 2.5; P + 9.4 ± 3.5 vs. 8.2 ± 2.8; T + 4.0 ± 1.4 vs. 3.4 ± 1.1). A + and P + peaked between 6-12 months of follow-up with a SUVmax of 7.6 ± 3.2, 10.6 ± 3.2, accordingly; T + peaked within 3-12 months with a SUVmax of 4.4 ± 1.4. Despite that A + and T + were more commonly seen in younger patients at any given study time, evident uptake rebound persisted in patients aged ≥16.
CONCLUSIONS: In paediatric patients with lymphoma, evident and benign rebound adenotonsillar and thymic 18F-FDG uptake commonly occur during post-treatment surveillance.
引用
- Hu YY, Zhao YM, Zhang X, et al. Rebound adenotonsillar and thymic uptake of 18F-FDG in paediatric patients with lymphoma. Eur J Radiol. 2020. PMID: 33099222. doi:10.1016/j.ejrad.2020.109348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。